Our top pick for
Bionano Genomics, Inc is a diagnostics & research business based in the US. Bionano Genomics shares (BNGO) are listed on the NASDAQ and all prices are listed in US Dollars. Bionano Genomics employs 97 staff and has a trailing 12-month revenue of around USD$8.4 million.
Since the stock market crash in March caused by coronavirus, Bionano Genomics's share price has had significant negative movement.
Its last market close was USD$0.5, which is 54.95% down on its pre-crash value of USD$1.11 and 28.21% up on the lowest point reached during the March crash when the shares fell as low as USD$0.39.
If you had bought USD$1,000 worth of Bionano Genomics shares at the start of February 2020, those shares would have been worth USD$425.54 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$495.05.
|Latest market close||USD$0.5|
|52-week range||USD$0.25 - USD$1.39|
|50-day moving average||USD$0.5885|
|200-day moving average||USD$0.5397|
|Wall St. target price||USD$1.48|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.759|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||-1.96%|
|1 month (2020-10-26)||-8.16%|
|3 months (2020-08-25)||-25.37%|
|6 months (2020-05-22)||6.38%|
|1 year (2019-11-25)||-48.18%|
|2 years (2018-11-22)||N/A|
|3 years (2017-11-22)||N/A|
|5 years (2015-11-22)||N/A|
|Revenue TTM||USD$8.4 million|
|Gross profit TTM||USD$3.4 million|
|Return on assets TTM||-71.65%|
|Return on equity TTM||-1464.01%|
|Market capitalisation||USD$82.9 million|
TTM: trailing 12 months
There are currently 5.8 million Bionano Genomics shares held short by investors – that's known as Bionano Genomics's "short interest". This figure is 6.8% up from 5.4 million last month.
There are a few different ways that this level of interest in shorting Bionano Genomics shares can be evaluated.
Bionano Genomics's "short interest ratio" (SIR) is the quantity of Bionano Genomics shares currently shorted divided by the average quantity of Bionano Genomics shares traded daily (recently around 7.4 million). Bionano Genomics's SIR currently stands at 0.78. In other words for every 100,000 Bionano Genomics shares traded daily on the market, roughly 780 shares are currently held short.
However Bionano Genomics's short interest can also be evaluated against the total number of Bionano Genomics shares, or, against the total number of tradable Bionano Genomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bionano Genomics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Bionano Genomics shares in existence, roughly 40 shares are currently held short) or 0.0401% of the tradable shares (for every 100,000 tradable Bionano Genomics shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bionano Genomics.
Find out more about how you can short Bionano Genomics stock.
We're not expecting Bionano Genomics to pay a dividend over the next 12 months.
Over the last 12 months, Bionano Genomics's shares have ranged in value from as little as $0.25 up to $1.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bionano Genomics's is 1.544. This would suggest that Bionano Genomics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.